primary effusion lymphoma
Showing 1 - 25 of >10,000
Lymphoma, Primary Effusion Trial run by the National Cancer Institute (NCI) (Daratumumab SC)
Not yet recruiting
- Lymphoma, Primary Effusion
- Daratumumab SC
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jun 23, 2023
Clinical and Genomic Factors for Prognosis of AIDS Primary
Recruiting
- AIDS-Related Primary Effusion Lymphoma
- Laboratory Biomarker Analysis
- Medical Chart Review
-
La Jolla, California
- +5 more
Jan 21, 2022
s From HIV Infection, KSHV Infection, Viral-Related
Recruiting
- HIV
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 25, 2023
AIDS-Related Burkitt Lymphoma, AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Plasmablastic Lymphoma Trial run by the
Active, not recruiting
- AIDS-Related Burkitt Lymphoma
- +5 more
- Prednisone
- +7 more
-
Bethesda, MarylandNCI Lymphoid Malignancies Branch
Jul 31, 2022
AIDS-related Non-Hodgkin Lymphoma, AIDS-related Plasmablastic Lymphoma, AIDS-related Primary Effusion Lymphoma Trial in Duarte
Active, not recruiting
- AIDS-related Non-Hodgkin Lymphoma
- +3 more
- busulfan
- +3 more
-
Duarte, CaliforniaCity of Hope Medical Center
Feb 17, 2022
ALK-Positive Large B-Cell Lymphoma, Burkitt-Like Lymphoma With 11q Aberration, DLBCL Activated B-Cell Type Trial in United
Active, not recruiting
- ALK-Positive Large B-Cell Lymphoma
- +34 more
- Nivolumab
- Varlilumab
-
Phoenix, Arizona
- +32 more
Jan 3, 2023
AIDS-Related Plasmablastic Lymphoma, AIDS-Related Primary Effusion Lymphoma, Ann Arbor Stage I DLBCL Trial in United States
Completed
- AIDS-Related Plasmablastic Lymphoma
- +15 more
- Cyclophosphamide
- +8 more
-
Montgomery, Alabama
- +34 more
Feb 23, 2022
Primary Mediastinal Large B-cell Lymphoma With CNS Involvement
Recruiting
- Primary Mediastinal Large B-cell Lymphoma (PMBCL)
-
Milan, ItalyOspedale San Raffaele
Aug 29, 2023
Pericardial Effusion Malignant Trial in Hong Kong (Percutaneous Balloon Pericardiotomy)
Recruiting
- Pericardial Effusion Malignant
- Percutaneous Balloon Pericardiotomy
-
Hong Kong, Shatin, Hong KongPrince of Wales Hospital
Mar 7, 2022
Primary CNS Lymphoma and Primary Vitreoretinal Lymphoma Trial (intensity-modulated radiotherapy (IMRT))
Not yet recruiting
- Primary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma
- intensity-modulated radiotherapy (IMRT)
- (no location specified)
Jun 4, 2023
CNS Involvement in Primary Mediastinal Large B-Cell Lymphoma
Active, not recruiting
- Primary Mediastinal Large B-cell Lymphoma (PMBCL)
- DISEASE
- (no location specified)
May 4, 2023
Primary Ocular Adnexal MALT Lymphoma Trial (Rituximab, Involved Site Radiation Therapy)
Not yet recruiting
- Primary Ocular Adnexal MALT Lymphoma
- Rituximab
- Involved Site Radiation Therapy
- (no location specified)
Sep 26, 2023
Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma, Primary Mediastinal Large B-Cell
Not yet recruiting
- Primary Mediastinal Large B-cell Lymphoma (PMBCL)
- +5 more
- Pembrolizumab
- +3 more
-
Boston, Massachusetts
- +1 more
Jun 28, 2023
Primary Vitreoretinal Lymphoma Trial in Beijing (Intravitreal injection of methotrexate)
Recruiting
- Primary Vitreoretinal Lymphoma
- Intravitreal injection of methotrexate
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Jul 11, 2023
Relapsed or Refractory (R/R) Primary CNS Lymphoma Trial in Nanjing (thiotepa combined with pomalidomide)
Recruiting
- Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma
- thiotepa combined with pomalidomide
-
Nanjing, Jiangsu, ChinaJiangsu Province People's Hospital.
Jun 27, 2023
Lung Cancer Trial in New York (GL-ONC1)
Active, not recruiting
- Lung Cancer
- GL-ONC1
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Feb 7, 2022
Diffuse Large B-cell Lymphoma Trial (Rituximab, Mitoxantrone HCl liposome, Cyclophosphamide)
Not yet recruiting
- Diffuse Large B-cell Lymphoma
- Rituximab
- +4 more
- (no location specified)
Mar 9, 2023
Primary CNS Lymphoma Trial in Hangzhou (Rituximab, Lenalidomide, Methotrexate)
Completed
- Primary Central Nervous System Lymphoma
- Rituximab
- +2 more
-
Hangzhou, Zhejiang, China2nd Affiliated Hospital, School of Medicine, Zhejiang University
Nov 18, 2022
Primary CNS Lymphoma Trial in Hanzhou (Orelabrutinib, Rituximab, Methotrexate)
Recruiting
- Primary Central Nervous System Lymphoma
- Orelabrutinib
- +2 more
-
Hanzhou, Zhejiang, China2nd Affiliated Hospital, School of Medicine, Zhejiang University
Nov 3, 2022
Diffuse Large B Cell Lymphoma (DLBCL) Trial in Toronto (glofitamab)
Not yet recruiting
- Diffuse Large B Cell Lymphoma (DLBCL)
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Sep 18, 2023
Refractory CNS Lymphoma, Relapsed Primary CNS Lymphoma, Primary CNS Lymphoma Trial in Hangzhou (Nivolumab)
Active, not recruiting
- Refractory Central Nervous System Lymphoma
- +2 more
-
Hangzhou, Zhejiang, ChinaJianmin Zhang
Jul 3, 2022
Primary CNS Lymphoma Trial in Beijing (Orelabrutinib,Rituximab and Methotrexate)
Recruiting
- Primary Central Nervous System Lymphoma
- Orelabrutinib,Rituximab and Methotrexate
-
Beijing, Beijing, ChinaHospital 307
Sep 19, 2022